ALNY Alnylam Pharmaceuticals, Inc.

50.46
+1  (2%)
Previous Close 49.56
Open 49.94
Price To book 4.63
Market Cap 4.34B
Shares 86,013,000
Volume 692,287
Short Ratio 12.01
Av. Daily Volume 935,082

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 trial to be initiated mid-2017.
Inclisiran
Hypercholesterolemia
Phase 1 additional data due June 2017 with a Phase 3 trial to be initiated in late 2017.
Givosiran
Acute hepatic porphyrias
Phase 1/2 trial initiated July 2016. Data are due mid 2017
ALN-HBV
Chronic hepatitis B virus (HBV)
Phase 1/2 initiated March 2016. Initial data released September 2016.
ALN-GO1
Primary Hyperoxaluria Type 1 (PH1)
Phase 3 data due mid 2017.
Patisiran APOLLO
Familial Amyloidotic Polyneuropathy (FAP) in Patients with ATTR
Phase 3 trial discontinued October 2016.
Revusiran ENDEAVOUR
ATTR in patients with familial amyloidotic cardiomyopathy (FAC)
Phase 1/2 initial data presented at ASH 2016.
ALN-CC5
Paroxysmal nocturnal hemoglobinuria (PNH)
Phase 3 program to be initiated 2Q 2017, with initial data due mid-late 2017
Fitusiran (ATLAS)
Hemophilia
Development plan to be confirmed following APOLLO data release in mid 2017.
ALN-TTRsc02
ATTR amyloidosis

Latest News

  1. Alnylam Pharmaceuticals, Inc. – Value Analysis (NASDAQ:ALNY) : April 20, 2017
  2. Alnylam Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : ALNY-US : April 19, 2017
  3. ($$) Beaten-Down Biotechs May Be Worth Buying
  4. 5 Deadliest Diseases in the U.S. -- and the Top Drugs Potentially on the Way to Treat Them
  5. Will Trump's FDA Chill Innovation Or Kill 'Astronomical' Prices?
  6. The 3 Best Cholesterol Drug Stocks to Buy in 2017
  7. Alnylam to Webcast Presentation at 16th Annual Needham Healthcare Conference
  8. Regeneron, Sanofi Look To Crush Amgen, And Rivals Say They Can
  9. Alnylam (ALNY) Up 14.5% Since Earnings Report: Can It Continue?
  10. Could Biogen Spinoff Bleed This Biotech In Hemophilia?
  11. ​Alnylam CEO’s pay fell nearly 80 percent in 2016
  12. Alnylam's LDL-Lowering Drug Positive in Phase II Study
  13. Esperion And Medicines Co. Recover From Amgen-Induced Pitfall
  14. Alnylam touts latest trial data as suggesting its drugs are safe
  15. The Medicines Company and Alnylam Pharmaceuticals Report Positive Final Results from ORION-1 Phase II Study of Inclisiran
  16. 5 Stocks The Best Performing Hedge Funds Are Piling Into
  17. Alnylam Receives European Medicines Agency PRIME Designation for Accelerated Assessment of Givosiran, an Investigational RNAi Therapeutic for the Treatment of Acute Hepatic Porphyrias
  18. Better Buy: bluebird bio, Inc. vs. Alnylam Pharmaceuticals
  19. Alnylam Pharmaceuticals’s Therapies to Treat hATTR Amyloidosis